Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY

Trending Activities
Bladder Cancer, Genitourinary Cancer, Immunotherapy
CE/CME ACCREDITED
touchPANEL DISCUSSION
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
Dr Axel Merseburger, Dr André Fay, Ms Maria Laupuente Translations available:
Watch Time: 39 mins

An oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies.

Learning objectives
Learning Objectives
  • Identify adverse events promptly in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
  • Use appropriate management strategies for the adverse events that arise in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
  • Apply a multidisciplinary approach to the identification and management of adverse events in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
Radiotherapy, Diagnostics and Screening, Radiology
CE/CME ACCREDITED
touchEXPERT OPINIONS
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Dr Ana Kiess, Dr Stephen Graves
Watch Time: 19 mins

Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity.

Learning objectives
Learning Objectives
  • Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
  • Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties

Curriculum Activities

Learn more with a series of activities which are linked and developed as a curriculum

Breast Cancer
touchCURRICULUM
Advanced Breast Cancer
 CME ACCREDITED

Watch interviews and expert perspectives covering the latest findings for treating HR+/HER2 Advanced Breast Cancer using CDK4/6 hinibitors from key cancer congresses throughout 2019.

Including:

touchCONGRESS

Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer

touchCONGRESS

Utilizing the latest data from SABCS 2020 to optimize the management of patients with HR+/HER2- breast cancer

Breast Cancer
Curriculum Inclusions:
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy
Breast Cancer
touchCURRICULUM
Considerations for optimizing care in patients with high-risk HR+ HER2- EBC: Insights from experts and the MDT
 CME ACCREDITED

Watch patient and expert perspectives on the latest strategies for the management of high-risk early breast cancer.

Including:

touchMDT

How can shared decision-making be successfully integrated to optimize care of patients with high-risk early breast cancer?

touchPANEL DISCUSSION

New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification and novel treatment strategies

Breast Cancer
Curriculum Inclusions:
  • Recognize the importance and relevance of shared decision-making in EBC care and apply it to clinical practice
  • Use strategies that help to stratify patients for their risk of recurrence of HR+ HER2- EBC
  • Appraise current and emerging treatment strategies for patients with HR+ HER2- EBC

All Activities

View all IME activities

Bladder Cancer, Genitourinary Cancer, Immunotherapy
Watch Time: 39 mins
touchPANEL DISCUSSION
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
CE/CME ACCREDITED Dr Axel Merseburger, Dr André Fay, Ms Maria Laupuente Translations available:

An oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies.

Learning objectives
Learning Objectives
  • Identify adverse events promptly in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
  • Use appropriate management strategies for the adverse events that arise in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
  • Apply a multidisciplinary approach to the identification and management of adverse events in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
Radiotherapy, Diagnostics and Screening, Radiology
Watch Time: 19 mins
touchEXPERT OPINIONS
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
CE/CME ACCREDITED Dr Ana Kiess, Dr Stephen Graves

Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity.

Learning objectives
Learning Objectives
  • Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
  • Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
Renal Cancer, Genitourinary Cancer, Immunotherapy
Watch Time: 51 mins
touchCONGRESS
Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: What have we learned from ASCO GU 2023?
CE/CME ACCREDITED Prof. Brian Rini, Prof. Elizabeth Plimack, Prof. Thomas Powles

Watch this touchCONGRESS activity exploring advances in immunotherapy treatments for patients with renal cell carcinoma. Filmed following ASCO GU 2023.

Learning objectives
Learning Objectives
  • Evaluate the latest efficacy and safety data for immune checkpoint inhibitor-based combinations in the treatment of advanced or metastatic RCC
  • Summarize the latest data on the use of biomarkers to predict response to immune checkpoint inhibitor-based combinations
  • Explain how the latest data on the use of immune checkpoint inhibitor-based combinations for the treatment of advanced or metastatic RCC may be implemented in clinical practice
Gastrointestinal Cancers
Watch Time: 35 mins
touchEXPERT OPINIONS
Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer: Current status and future perspectives
CE/CME ACCREDITED Dr Reetu Mukherji, Dr Jaffer Ajani, Dr Nataliya Uboha

Watch three experts provide their insights on unmet needs, emerging therapies, and the importance of biomarker testing in HER2-negative GC/GEJC.

Learning objectives
Learning Objectives
  • Describe the burden of disease and unmet treatment needs for patients with advanced HER2-negative GC/GEJC
  • Discuss the evidence for novel and emerging first-line targeted treatments for patients with HER2-negative advanced GC/GEJC
  • Explain the importance of biomarker testing for selection of targeted therapies in advanced GC/GEJC
Immunotherapy
Watch Time: 39 mins
touchPANEL DISCUSSION
Improving outcomes of immune-related adverse events: The crucial role of the pharmacist
CE/CME ACCREDITED Dr Sandra Cuellar, Dr Sonia Amin Thomas, Ms Meera Desai

Watch three experts in oncological pharmacology discuss how to improve outcomes for patients experiencing irAEs after receiving immunotherapy.

Learning objectives
Learning Objectives
  • Recognize the importance of the community, outpatient or ambulatory care pharmacist in improving outcomes related to irAEs
  • Summarize the challenges associated with the recognition and management of irAEs
  • Formulate a strategy for monitoring and managing irAEs alongside other members of the multidisciplinary team
Colorectal Cancer, Gastrointestinal Cancers
Watch Time: 45 mins
touchPANEL DISCUSSION
Optimizing strategies for the treatment of colorectal cancer in the biomarker era
CE/CME ACCREDITED Dr Kei Muro, Dr Chiara Cremolini, Dr Rachel Riechelmann Translations available:

Dr Muro, Dr Cremolini and Dr Riechelmann discuss how biomarkers can guide treatment choices for patients with colorectal cancer.

Learning objectives
Learning Objectives
  • Compare and contrast the available techniques for biomarker testing recommended for patients with CRC
  • Compare and contrast the available techniques for biomarker testing recommended for patients with CRC
  • Review the evidence for recent and emerging targeted therapy options for CRC
Haematology, Diagnostics and Screening
Watch Time: 37 mins
touchPANEL DISCUSSION
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
CE/CME ACCREDITED Dr Rachael Grace, Dr Hanny Al-Samkari, Dr Ami J Shah

Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.

Learning objectives
Learning Objectives
  • Recognize the signs and symptoms of PK deficiency and the burden of disease in affected patients
  • Evaluate established therapeutic strategies for PK deficiency and identify remaining unmet treatment needs
  • Describe novel and emerging therapeutic strategies for PK deficiency and how they may address current unmet needs
Lung Cancer, Immunotherapy
Watch Time: 48 mins
touchMDT
Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations
CE/CME ACCREDITED Prof. Raffaele Califano, Prof. Lisa Holle, Prof. Albrecht Stenzinger and Mr Josh Colow Translations available:

Leading specialists and a patient advocate discuss novel immunotherapies for non-driver mutation metastatic non-small cell lung cancer (NSCLC).

Learning objectives
Learning Objectives
  • Outline the determinants of response and resistance to immune checkpoint blockade in patients with non-driver mutation metastatic NSCLC
  • Discuss the mechanisms of action and latest data for novel immunotherapy regimens in the management of non-driver mutation metastatic NSCLC
  • Appraise strategies for involving patients with non-driver mutation metastatic NSCLC in their healthcare for optimal outcomes
Colorectal Cancer, Gastrointestinal Cancers
Watch Time: 47 mins
touchMDT
How can HER2-targeted therapies be incorporated into the management of patients with CRC?
CE/CME ACCREDITED Prof. Andrea Sartore-Bianchi, Dr Evgeny Yakirevich, Dr Kristen Ciombor, Dr Kelley Rone, Mr Scott Wilson

Hear multidisciplinary team and patient perspectives on the management of HER2-positive colorectal cancer.

Learning objectives
Learning Objectives
  • Summarize how to test for HER2 amplifications in patients with CRC and how to interpret the results
  • Discuss how HER2-targeted agents can be incorporated into the management of patients with CRC
  • Outline how the multidisciplinary team can support patients with HER2+ CRC
Haematological Malignancies, Haematology
Watch Time: 34 mins
touchTALKS
What’s on the horizon for higher-risk MDS? An update on emerging novel agents
CE/CME ACCREDITED Dr David Sallman

Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.

Learning objectives
Learning Objectives
  • Recall the mechanisms of action for key emerging treatments for patients with HR-MDS
  • Describe the latest efficacy data for key emerging treatments for patients with HR-MDS
  • Discuss the safety profile of key emerging treatments for patients with HR-MDS
Lung Cancer
Watch Time: 38 mins
touchMDT
Continuing the momentum in SCLC: Exploring second-line and novel therapy options
CE/CME ACCREDITED Dr Barbara Melosky, Dr Sonia Amin Thomas, Dr Christine Argento, Dr Victoria Sherry

MDT specialists discuss the current and emerging second-line treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC)

Learning objectives
Learning Objectives
  • Describe the current and emerging second-line treatment options for patients with SCLC
  • Identify patient- and disease-related factors that affect treatment decisions for patients with SCLC in the second-line setting
  • Describe strategies to manage adverse events for patients with SCLC in the second-line treatment setting
Colorectal Cancer, Gastrointestinal Cancers
Watch Time: 34 mins
touchPANEL DISCUSSION
What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
CE/CME ACCREDITED Dr Ian Chau, Dr Antonia Sepulveda, Dr Silvia Marsoni

Watch three experts discuss testing and treatment guidelines for HER2+ colorectal cancer (CRC) and clinical trial data for HER2-targeted therapies.

Learning objectives
Learning Objectives
  • Explain the testing methods used to identify patients with human epidermal growth factor receptor 2-positive (HER2+) colorectal cancer (CRC) and the interpretation of the results
  • Summarize the current guidelines for managing patients with HER2+ CRC
  • Discuss the recent efficacy and safety data for HER2-targeted agents in CRC
Immunotherapy
Watch Time: 37 mins
touchPANEL DISCUSSION
Immunogenicity of immune checkpoint inhibitors: What are the implications for clinical practice?
CE/CME ACCREDITED Prof. Peter Galle (CHAIR), Dr Vibeke Strand, Dr Victor Moreno Translations available:

Watch three experts discuss the clinical relevance of the immunogenicity of immune checkpoint inhibitors for the treatment of cancer, informed by experience in inflammatory diseases.

Learning objectives
Learning Objectives
  • Describe the experience of immunogenicity from the use of biologic therapies in chronic inflammatory diseases, and how this might inform the use of immune checkpoint inhibitors in oncology
  • Review the current data for the immunogenicity of immune checkpoint inhibitors and how anti-drug antibodies impact drug efficacy and safety
  • Discuss the potential clinical implications of ADAs in oncology and possible strategies for management
Haematology
Watch Time: 25 mins
touchEXPERT OPINIONS
Getting personal: Individualizing therapy for cold agglutinin disease
CE/CME ACCREDITED Dr Catherine M Broome, Dr Ilene Ceil Weitz

Watch two experts give their perspectives on the recommended workup for a timely and accurate diagnosis, as well as the evolving treatment landscape, and the importance of individualizing therapy for patients with cold agglutinin disease.

Learning objectives
Learning Objectives
  • Outline strategies for the accurate diagnosis of cold agglutinin disease
  • Evaluate the current and emerging treatment options for patients with cold agglutinin disease using the latest data
  • Assess potential strategies for individualizing the treatment for patients with cold agglutinin disease
Haematology, Immunotherapy
Watch Time: 32 mins
touchPANEL DISCUSSION
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
CE/CME ACCREDITED Prof. Morie Gertz, Prof. Bernd Jilma, Dr Shirley D'Sa

Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.

Learning objectives
Learning Objectives
  • Describe the immunopathogenesis of cold agglutinin disease (CAD) and implications for effective patient management
  • Appraise current and emerging treatment options for patients with CAD using the latest data
  • Evaluate strategies to individualize the treatment and management of patients with CAD
Bladder Cancer, Genitourinary Cancer, Immunotherapy
Watch Time: 59 mins
touchCONGRESS
Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022
CE/CME ACCREDITED Prof. Axel Merseburger, Dr Bradley McGregor, Prof. Andrea Necchi

Watch this two-part activity exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. Filmed following the ESMO 2022 Congress. Part 1: Watch urological cancer expert Prof. Axel Merseburger review key data from the ESMO Congress 2022 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

Learning objectives
Learning Objectives
  • Recall the latest efficacy data for new and emerging targeted treatments for patients with bladder cancer
  • Describe the safety profile of new and emerging targeted treatments for patients with bladder cancer
  • Discuss how the latest data on targeted treatments may affect the current and future management of patients with bladder cancer
Breast Cancer
Watch Time: 38min
touchIN CONVERSATION
Navigating the evolving treatment landscape in mTNBC: What are the key considerations for clinical practice today?
CE/CME ACCREDITED Prof. Peter Schmid, Dr Marleen Kok Translations available:

Two breast cancer specialists discuss the mechanisms of action and latest data on emerging drug classes and how they are changing the management of metastatic triple negative breast cancer (mTNBC).

Learning objectives
Learning Objectives
  • Evaluate clinical evidence for the use of immune checkpoint inhibitors (ICIs) in PD-L1-positive mTNBC in the first-line setting and its applicability to clinical practice
  • Translate the latest clinical evidence for approved and emerging ADCs for patients with mTNBC into current and future clinical practice
  • Outline the potential for targeted therapy with PARP inhibitors in the BRCA-mutated TNBC treatment landscape
Endocrine Cancers, Diagnostics and Screening
Watch Time: 45 mins
touchMDT
Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
CE/CME ACCREDITED Dr Diane Reidy-Lagunes, Prof. Dr med. Marianne Pavel, Dr Thomas Hope, Catherine Bouvier Ellis

Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.

Learning objectives
Learning Objectives
  • Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
  • Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
  • Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
Lung Cancer, Immunotherapy
Watch Time: 35 mins
touchPANEL DISCUSSION
Exploring the latest advances in first-line treatment of ES-SCLC: Translating the data to clinical practice
CE/CME ACCREDITED Dr Marina Garassino, Dr Luis Paz-Ares, Dr Martin J Edelman Translations available:

Watch leading lung cancer experts share their insights on the latest advancements in first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

Learning objectives
Learning Objectives
  • Recall the latest data on the efficacy of ICI-combination approaches for ES-SCLC in the first-line setting
  • Describe the latest safety data for ICI-combination approaches for patients with ES-SCLC
  • Discuss ongoing ICI clinical trial data and preclinical trials in ES-SCLC
Renal Cancer, Genitourinary Cancer, Immunotherapy
Watch Time: 35 mins
touchIN CONVERSATION
Improving outcomes for patients with advanced RCC: What is the role of emerging combination therapies in the first-line setting?
CE/CME ACCREDITED Dr Toni Choueiri, Dr Cristina Suárez

Watch genitourinary oncology experts discuss how emerging combination therapies in the first-line treatment of advanced RCC can improve patient outcomes.

Learning objectives
Learning Objectives
  • Evaluate the rationale for the use of combination therapy in patients with advanced RCC
  • Discuss the latest efficacy and safety data for established and emerging combination therapies in first-line advanced RCC
  • Apply best practice in the management of adverse events associated with combination therapies for first-line advanced RCC
Breast Cancer, Diagnostics and Screening
Watch Time: 41 mins
touchPANEL DISCUSSION
New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification and novel treatment strategies
CE/CME ACCREDITED Dr Carlos Barrios, Prof. Dr. med. Nadia Harbeck, Prof. Chiun-Sheng Huang Translations available:

Watch leading breast cancer specialists share their perspectives on risk stratification and future therapies in HR+ HER2- early breast cancer.

Learning objectives
Learning Objectives
  • Apply appropriate risk assessment and stratification strategies to predict patients’ likely risk of disease recurrence
  • Evaluate the latest guidelines and treatment options for the management of high-risk HR+ HER2- early breast cancer and assess the remaining unmet need
  • Interpret the evidence for novel therapeutic options for high-risk HR+ HER2- early breast cancer
Multiple Myeloma, Haematological Malignancies
Watch Time: 34 mins
touchIN CONVERSATION
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
CE/CME ACCREDITED Dr Faith Davies, Dr E Randolph Broun

A multiple myeloma expert and a community oncologist discuss real-world evidence for frail/elderly patients and its application in practice.

Learning objectives
Learning Objectives
  • Explain the role and importance of real-world evidence (RWE) in supporting clinical decision making
  • Outline the key RWE related to the treatment of elderly and frail patients with multiple myeloma
  • Discuss the management of elderly and frail patients with multiple myeloma in clinical practice
Head and Neck Cancer
Watch Time: 38 mins
touchPANEL DISCUSSION
Navigating the challenges of treatment provision in recurrent/metastatic head and neck squamous cell carcinoma
CE/CME ACCREDITED Prof. Lisa Licitra, Dr Aline Chaves, Prof. Joël Guigay Translations available:

Three experts consider the optimal management of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Learning objectives
Learning Objectives
  • Recall the latest data for the treatment of recurrent/metastatic HNSCC
  • Use the latest data to select the most appropriate treatment for patients with recurrent/metastatic HNSCC
  • Explain the importance of establishing patient preferences and priorities in treatment decision-making
Prostate Cancer
Watch Time: 32 mins
touchMDT
PARP inhibitors in prostate cancer: New combinations, new possibilities
CE/CME ACCREDITED Dr Wassim Abida, Dr Lisa Holle, Prof. Axel Merseburger

Watch leading specialists discuss new PARP inhibitor combinations for the treatment of advanced prostate cancer

Learning objectives
Learning Objectives
  • Analyse the mechanism of action of PARP inhibitors and the biological and clinical rationale for PARP inhibitor combinations in the treatment of advanced prostate cancer
  • Discuss key data from clinical trials with PARP inhibitor combinations in the management of advanced prostate cancer
  • Recognize the potential for extended benefit of PARP inhibitor combinations in advanced prostate cancer beyond HRR gene mutations
Gynaecological Cancers
Watch Time: 32 mins
touchMDT
Shifting the focus to locally advanced cervical cancer: Improving patient outcomes through multidisciplinary teamwork
CE/CME ACCREDITED Prof. Cyrus Chargari, Dr Mary McCormack, Prof. Bradley Monk, Ms Kathleen Smith Translations available:

MDT specialists discuss the current standard of care for patients with locally advanced cervical cancer in light of recent data, and highlight the role of the MDT in improving outcomes for patients through improved collaboration and optimization of the patient journey.

Learning objectives
Learning Objectives
  • Recall the heterogeneity of patients and prognostic risk factors in locally advanced cervical cancer (LACC) and how they affect clinical decision-making
  • Describe the use of current treatment strategies for LACC and best practices for effective management
  • Recognize the importance of the multidisciplinary team in optimizing outcomes in LACC and as early adopters of emerging treatment options
Breast Cancer, Supportive Cancer Care
Watch Time: 42 mins
touchMDT
How can shared decision-making be successfully integrated to optimize care of patients with high-risk early breast cancer?
CE/CME ACCREDITED Prof. Frances Boyle, Prof. Dr Khatijah Lim Abdullah, Prof. Dr Michael Gnant, Ms Evelyn Ong Translations available:

Watch leading breast cancer specialists within an MDT, plus an early breast cancer (EBC) survivor, share their perspectives on shared decision-making (SDM).

Learning objectives
Learning Objectives
  • Recognize the importance and relevance of SDM in the context of EBC
  • Evaluate the evidence for the effect that SDM has in optimizing outcomes for patients with breast cancer
  • Assess the challenges of implementing SDM and formulate strategies to overcome them
Dermatological Cancers, Head and Neck Cancer, Immunotherapy, Supportive Cancer Care
Watch Time: 48 mins
touchMDT
Optimizing the patient journey in CSCC through multidisciplinary collaboration
CE/CME ACCREDITED Prof. Caroline Robert, Dr Kluas Busam, Dr Agata Rembielak, Prof. Francesco Bussu, Dr Joël Claveau Translations available:

In this activity, leading experts discuss optimal approaches for the management of patients with CSCC and consider how effective multidisciplinary collaboration can contribute to improved outcomes.

Learning objectives
Learning Objectives
  • Define multidisciplinary best practices for diagnostic workup of cutaneous squamous cell carcinoma (CSCC) and identification of risk factors influencing prognosis
  • Outline interdisciplinary eligibility criteria for surgery and radiotherapy in patients with CSCC
  • Determine the optimal use of systemic therapies in patients with unresectable locally advanced or metastatic CSCC and the role of the multidisciplinary tumour board in sharing clinical decisions in cancer care
Diagnostics and Screening, Head and Neck Cancer, Supportive Cancer Care
Watch Time: 41 mins
touchEXPERT OPINIONS
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
CE/CME ACCREDITED Prof. Maria Cabanillas, Dr Vivek Subbiah, Dr Lori Wirth

Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers

Learning objectives
Learning Objectives
  • Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
  • Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
  • Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Bladder Cancer, Genitourinary Cancer
Watch Time: 31 mins
touchTALKS
The evolving role of antibody⁠-drug conjugates in the treatment of urothelial carcinoma
CE/CME ACCREDITED Dr Cora Sternberg

Dr Cora Sternberg considers the use of antibody–drug conjugates in urothelial carcinoma, including clinical trial data and adverse event management.

Learning objectives
Learning Objectives
  • Describe the rationale for and current role of antibody–drug conjugates in the treatment of urothelial carcinoma
  • Discuss efficacy data for current and emerging antibody–drug conjugates in the treatment of urothelial carcinoma
  • Explain the safety profile of antibody–drug conjugates in patients with urothelial carcinoma and approaches to managing possible adverse events
Head and Neck Cancer, Immunotherapy
Watch Time: 33 mins
touchPANEL DISCUSSION
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations?
CE/CME ACCREDITED Prof. Kevin Harrington, Prof. Barbara Burtness, Prof. Jean-Pascal Machiels

Three experts explore the clinical application of immune checkpoint inhibitors for patients with recurrent or metastatic HNSCC.

Learning objectives
Learning Objectives
  • Outline how key clinical trial data for immune checkpoint inhibitors in recurrent or metastatic HNSCC can be applied to clinical practice
  • Discuss factors that may help guide the use of immune checkpoint inhibitors for patients with recurrent or metastatic HNSCC
  • Formulate a strategy to monitor for and manage the possible adverse events of immune checkpoint inhibitors
Gynaecological Cancers, Head and Neck Cancer, Immunotherapy
Watch Time: 34 mins
touchEXPERT OPINIONS
HPV infection and TGF-β: Translating the science into treatments for HPV-associated cancers
CE/CME ACCREDITED Dr Judith Michels, Dr Andrew Sikora, Dr Krishnansu Tewari Translations available:

Watch leading experts review the management of HPV-associated cancers and the biological pathways that are driving the development of new treatments.

Learning objectives
Learning Objectives
  • Describe the current unmet needs for patients with advanced HPV-associated cancers
  • Recognize the link between HPV infection and TGF-β in HPV-associated cancers
  • Recall the mechanisms of action and latest data for agents targeting HPV or TGF-β for the treatment of HPV-associated cancers
Prostate Cancer, Genitourinary Cancer, Immunotherapy
Watch Time: 34 mins
touchEXPERT OPINIONS
Immune checkpoint inhibitors in prostate cancer: Current and future practice
CE/CME ACCREDITED Prof. Karim Fizazi, Dr Sandy Srinivas, Prof. Johann de Bono

Watch leading experts consider the current role of immune checkpoint inhibitors in prostate cancer and possible future directions.

Learning objectives
Learning Objectives
  • Discuss the current use of immune checkpoint inhibitors for prostate cancer
  • Identify patients who might benefit from immune checkpoint inhibitors using biomarkers
  • Describe emerging treatment approaches, such as combination therapies
Watch Time: 33 mins
touchMDT
Evolving standards of patient care in hepatocellular carcinoma
CE/CME ACCREDITED Prof. Ahmed Kaseb, Prof. Jinsil Seong, Prof. Peter Galle, Dr Michael Choti

Select a discussion in the hub to watch our multidisciplinary faculty share their expert perspectives on the management of patients with hepatocellular carcinoma.

Learning objectives
Learning Objectives
  • Analyze the importance of a multidisciplinary approach to patient care in the management of HCC
  • Appraise optimal treatment pathways for individual patients and unmet needs in the management of HCC
  • Evaluate the future role of immune checkpoint inhibitors in the management of HCC
Diagnostics and Screening, Head and Neck Cancer, Supportive Cancer Care
Watch Time: 49 mins
touchMDT
Implementing a personalized approach to treatment of thyroid cancer: the importance of biomarker testing and targeted therapies
CE/CME ACCREDITED Dr Lori Wirth, Dr Peter Sadow, Dr Antonio Matrone, Ms Tara Hurley Translations available:

Watch leading specialists within an MDT discuss the importance of biomarker testing and targeted therapies for personalizing management of thyroid cancer

Learning objectives
Learning Objectives
  • Distinguish between different types of thyroid cancers and identify appropriate therapies for their management
  • Plan for the use of precision medicine in thyroid cancer, including implementation of biomarker testing and use of novel targeted therapies
  • Evaluate the clinical trial data for novel targeted therapies for thyroid cancer and translate it into clinical practice
Lung Cancer
Watch Time: 42 mins
touchMDT
Navigating diagnostic considerations and treatment options in NSCLC: A multidisciplinary approach
CE/CME ACCREDITED Dr Alexander Drilon, Prof. Keith Kerr, Dr Marianne Davies, Prof. Andrea Bezjak

Watch leading experts involved in the multidisciplinary management of patients with advanced NSCLC discuss the importance of the initial assessment and key considerations for treatment choices within a rapidly evolving landscape.

Learning objectives
Learning Objectives
  • Discuss the significance of the MDT for prompt and effective diagnosis and treatment selection in NSCLC
  • Evaluate the utility of broad molecular profiling and companion diagnostics within the context of current recommendations for molecular testing in NSCLC
  • Recall the latest therapeutic developments in advanced NSCLC and implications for MDT clinical decision making
Breast Cancer
Watch Time: 33 mins
touchPANEL DISCUSSION
Expanding options for HER2 advanced breast cancer: Taking trial data to the clinic
CE/CME ACCREDITED Dr Laura Biganzoli, Dr Sonia Pernas, Dr Peter Fasching

Three experts discuss emerging treatments for HER2-directed therapies for advanced breast cancer and the implications for clinical practice

Learning objectives
Learning Objectives
  • Evaluate the latest efficacy data for different HER2-targeted therapies in advanced breast cancer
  • Apply appropriate monitoring for and management of adverse events in patients receiving HER2-targeted therapies
  • Describe how novel approaches to HER2-targeting for advanced breast cancer in development may impact clinical practice
Breast Cancer
Watch Time: 33 min
touchPANEL DISCUSSION
The emerging role of SERDs in HR+ breast cancer: Which patients may benefit most in clinical practice?
CE/CME ACCREDITED Prof. Hope S Rugo, Dr Matti Aapro, Dr Fatima Cardoso

Watch experts in breast cancer management discuss the use of current and emerging SERDs in treating HR+ breast cancer.

Learning objectives
Learning Objectives
  • Describe the evolving treatment landscape for HR+ breast cancer
  • Distinguish breast cancer populations of special interest and understand the potential impact on the management and treatment of disease in these patients
  • Assess the potential of emerging SERDs in the context of the current treatment landscape for breast cancer
Lung Cancer
Watch Time: 38 mins
touchPANEL DISCUSSION
Deciphering the data in EGFR-mutant NSCLC: What have we learned in 2021?
CE/CME ACCREDITED Dr Pasi Jänne, Dr Thanyanan Reungwetwattana, Dr Neal Navani Translations available:

Watch experts in lung cancer discuss the evolving treatment options for patients with EGFR-mutant NSCLC, as well as the importance of biomarker testing in determining the best treatment approaches for patients with early-stage or metastatic disease.

Learning objectives
Learning Objectives
  • Describe how the use of EGFR-TKIs in patients with EGFR-mutant NSCLC is evolving
  • Explain the importance of timely biomarker testing at diagnosis and throughout treatment for patients with EGFR-mutant NSCLC
  • Recall latest data for therapy options post-resistance to EGFR-TKIs in patients with advanced EGFR-mutant NSCLC
Lung Cancer
Watch Time: 33 mins
touchPANEL DISCUSSION
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
CE/CME ACCREDITED Prof. Egbert Smit (CHAIR), Dr Jarushka Naidoo, Dr Katerina Politi Translations available:

Watch a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC.

Learning objectives
Learning Objectives
  • Describe the various HER2 alterations in NSCLC and the potential role of HER2 as a therapeutic target
  • Discuss current treatment approaches for patients with HER2-mutant NSCLC and associated survival outcomes
  • Recall the efficacy and safety data for novel HER2-targeted therapies for HER2-mutant NSCLC
Endocrine Cancers, Gastrointestinal Cancers, Pancreatic Cancer
Watch Time: 36 mins
touchPANEL DISCUSSION
Perspectives on the current status and recent advances in GEP-NETs
CE/CME ACCREDITED Prof. Jonathan R Strosberg, Dr Jennifer Chan, Prof. Dr. med. Marianne Pavel

Explore current perspectives on the management of GEP-NETs through this panel discussion, highlighting emerging data presented at the ESMO Congress 2021.

Multiple Myeloma, Haematological Malignancies, Haematology
Watch Time: 36 mins
touchPANEL DISCUSSION
Keeping pace with the evolving treatment paradigm for relapsed/refractory multiple myeloma: Earlier use of novel agents
CE/CME ACCREDITED Dr Nina Shah, Dr Cristina Gasparetto, Prof. Xavier Leleu

Three international experts discuss how novel agents approved for early lines of therapy are changing the landscape of RRMM treatment.

Learning objectives
Learning Objectives
  • Recall the role of novel therapies earlier in the treatment pathway for RRMM
  • Discuss the trials utilizing novel agents earlier in the treatment pathway for RRMM
  • Use appropriate supportive care measures when initiating patients with RRMM on a novel agent
Dermatological Cancers, Immunotherapy
Watch Time: 37 mins
touchEXPERT OPINIONS
Navigating the emerging complexities of melanoma treatment: New insights for clinical practice
CE/CME ACCREDITED Dr Ana Arance; Prof. Paolo Ascertio; Dr Allison Betof Warner

Watch leading experts discuss evolving neoadjuvant, adjuvant and metastatic treatment options for patients with melanoma, taking in the latest data presented at the ESMO Congress 2021.

Learning objectives
Learning Objectives
  • Describe the long-term survival results in patients with melanoma and their relevance to treatment decisions
  • Evaluate current strategies to improve outcomes for patients with melanoma who do not experience a durable response
  • Recall the latest data for emerging treatment options, including the use of triple combination approaches, and how these therapies fit into the melanoma treatment paradigm
Lung Cancer, Immunotherapy
Watch Time: 64 mins
touchCONGRESS
Optimizing frontline immunotherapy for advanced NSCLC
CE/CME ACCREDITED Prof. Edward Garon, Prof. Anne-Marie Dingemans, Dr Raffaele Califano Translations available:

Watch this two-part activity exploring recent developments on the use of frontline immunotherapeutic strategies in patients with advanced non-small cell lung cancer (NSCLC). Filmed following the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and European Society for Medical Oncology (ESMO) Congress 2021. Part 1: Watch thoracic oncology expert Prof. Edward Garon review key data from the 2021 ASCO Annual Meeting and ESMO Congress 2021 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

Learning objectives
Learning Objectives
  • Summarize recent data evaluating frontline single-agent immunotherapy or combination strategies for advanced NSCLC
  • Assess potential biomarkers that may be used to identify patients with advanced NSCLC who may benefit from frontline immunotherapy
  • Outline effective management strategies using frontline immunotherapeutic strategies for patients with advanced NSCLC
Dermatological Cancers, Head and Neck Cancer, Immunotherapy
Watch Time: 34 mins
touchEXPERT OPINIONS
Immunotherapy and evolving approaches for basal cell carcinoma
CE/CME ACCREDITED Prof. Axel Hauschild, Dr Emily Ruiz, Prof. Ketty Peris Translations available:

Watch leading experts discuss evolving treatment options for patients with advanced basal cell carcinoma, and how novel immunotherapeutic approaches within the emerging clinical study landscape may improve patient care.

Learning objectives
Learning Objectives
  • Recognize the current unmet needs and rationale for alternative treatment options for patients with basal cell carcinoma (BCC)
  • Evaluate the latest data for using immunotherapy to treat patients with advanced BCC
  • Define how the latest advances in BCC may impact clinical practice
Lung Cancer
Watch Time: 41 mins
touchMDT
Continually improving care: Evolving role of the MDT in early EGFR-mutant NSCLC
CE/CME ACCREDITED Dr David Planchard, Prof. Johan Vansteenkiste, Dr Masahiro Tsuboi, Prof. Albrecht Stenzinger, Ms Beth Sandy Translations available:

Watch leading specialists from the multidisciplinary tumour board discuss optimal approaches to managing patients with early-stage NSCLC, with or without an EGFR driver mutation  

Endocrine Cancers, Gastrointestinal Cancers, Pancreatic Cancer
Watch Time: 35 mins
touchEXPERT OPINIONS
Optimizing the management of gastroenteropancreatic neuroendocrine tumours
CE/CME ACCREDITED Prof. Jonathan R Strosberg, Dr Diane Reidy-Lagunes, Prof. Thorvardur R Halfdanarson

Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.

Lung Cancer
Watch Time: 37 mins
touchEXPERT OPINIONS
Moving MET into the clinic: Latest evidence for MET inhibitors in NSCLC
CE/CME ACCREDITED Dr Enriqueta Felip, Dr Rebecca S Heist, Dr Takashi Seto Translations available:

Watch leading experts review the latest clinical data from ASCO 2021 on the role of MET inhibitors in NSCLC and the importance of identifying patients who may benefit from a targeted approach

Learning objectives
Learning Objectives
  • Recall the latest efficacy data from MET-inhibitor clinical trials in NSCLC
  • Describe diagnostic methods for the identification of MET exon 14 skipping mutations and MET amplification
  • Discuss practical adverse event management with MET inhibitors in the clinic
Gynaecological Cancers
Watch Time: 42 mins
touchEXPERT OPINIONS
The evolving clinical landscape of biologic therapy for patients with recurrent/metastatic cervical cancer
CE/CME ACCREDITED Prof. Christian Marth, Prof. Susana Campos, Prof. Ignace Vergote

Watch leading experts review the latest clinical data and guideline recommendations supporting the use of biologic therapies in recurrent/metastatic cervical cancer.

Learning objectives
Learning Objectives
  • Describe current and emerging immunotherapy approaches for the treatment of recurrent/metastatic cervical cancer
  • Recall the latest clinical efficacy data for biologic therapies in recurrent/metastatic cervical cancer
  • Discuss selection of biologic therapies for patients with recurrent/metastatic cervical cancer, adverse event management and future directions for treatment guidelines
Colorectal Cancer
Watch Time: 34 mins
touchEXPERT OPINIONS
Optimizing targeted therapy in colorectal cancer: How do the latest data impact clinical practice?
CE/CME ACCREDITED Prof. Rachel Riechelmann, Dr Diana Hanna, Prof. Takayuki Yoshino Translations available:

Watch three oncology experts discuss advances in targeted therapies and biomarkers for metastatic colorectal cancer (CRC).

Learning objectives
Learning Objectives
  • Identify appropriate first-line therapies for patients with colorectal cancer according to the primary tumour site and molecular profile
  • Discuss the rationale for rechallenge using anti-EGFR therapies and the potential treatment benefits for patients with CRC
  • Analyse the most recent data for therapy for patients with BRAF-mutation-positive colorectal cancer
Prostate Cancer
Watch Time: 32 mins
touchTALKS
Improving outcomes in prostate cancer: What is the role of PARP-inhibitor combination therapy?
CE/CME ACCREDITED Dr Neal Shore, Translations available:

Watch Dr Neal Shore discuss the use of PARP inhibitors for patients with mCRPC and consider their potential as combination treatment with androgen deprivation therapy.

Learning objectives
Learning Objectives
  • Discuss the use of combination PARP-inhibitor targeted therapy in the management of prostate cancer
  • Evaluate how to select/identify patients for potential combination PARPi and androgen receptor targeted therapy for prostate cancer
  • Review ongoing clinical trials exploring combination PARPi and androgen-receptor targeted therapy for prostate cancer
Multiple Myeloma
Watch Time: 33 mins
touchPANEL DISCUSSION
Improving outcomes in multiple myeloma with new treatment targets
CE/CME ACCREDITED Prof. Joseph Mikhael, Dr Cristina Gasparetto, Dr Elena Zamagni

Watch a panel of experts discuss how novel targeted therapies are changing the treatment paradigm for multiple myeloma to achieve the best outcomes for patients.

Learning objectives
Learning Objectives
  • Recall the mechanisms of action and data for relapsed/refractory multiple myeloma treatments with novel agents
  • Discuss the adverse event (AE) profiles of treatments with novel targets and how AEs could be managed in clinical practice
  • Describe the possible role of agents with novel targets earlier in the multiple myeloma treatment pathway
Haematological Malignancies, Haematology, Lymphoma
Watch Time: 40 mins
touchEXPERT OPINIONS
New and emerging strategies for managing patients with relapsed/refractory follicular lymphoma: latest advances in prognostics and treatment
CE/CME ACCREDITED Prof. Kami Maddocks, Dr Connie Lee Batlevi, Dr Laurie Sehn

Watch leading lymphoma specialists provide updates on prognostic factors and novel treatment strategies for patients with relapsed/refractory follicular lymphoma

Learning objectives
Learning Objectives
  • Evaluate the key prognostic factors that indicate high risk of inferior outcomes in patients with FL
  • Evaluate novel and emerging treatment strategies for patients with R/R FL
  • Translate the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL into clinical practice
Lung Cancer
Watch Time: 42 mins
touchEXPERT OPINIONS
Current treatment paradigm and future prospects for extensive-stage small cell lung cancer in the relapsed setting
CE/CME ACCREDITED Prof. Taofeek Owonikoko, Dr Viola Zhu, Prof. Giuseppe Giaccone

Watch three oncology specialists discuss the latest advances in the treatment of extensive-stage small cell lung cancer (SCLC).

Learning objectives
Learning Objectives
  • Summarize the current treatment recommendations for SCLC and how they are evolving as new agents emerge
  • Evaluate the efficacy and safety of emerging agents for relapsed SCLC
  • Describe emerging treatment options and ongoing clinical trials for relapsed SCLC
Breast Cancer
Watch Time: 67 mins
touchCONGRESS
Utilizing the latest data from SABCS 2020 to optimize the management of patients with HR+/HER2- breast cancer
CE/CME ACCREDITED Professor Nadia Harbeck Translations available:

Watch this two-part activity discussing the latest developments in the management of early breast cancer. Filmed following the SABCS Virtual Congress 2020.  Part 1:  Watch internationally renowned expert Prof. Nadia Harbeck review key data from the SABCS Congress Watch Now Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice Select An Interview For subtitles in Spanish and Brazilian Portuguese, please click [CC] on the video player below.

Learning objectives
Learning Objectives
  • Apply new and emerging data for CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer in clinical practice
  • Use the latest results for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer to inform treatment decisions in clinical practice
  • Review emerging real-world data on the outcome of patients with active or a history of cancer who have developed COVID-19 during the COVID-19 pandemic
Breast Cancer
Watch Time: 64 mins
touchCONGRESS
Utilizing the latest data from ESMO 2020 to optimize the management of patients with HR+/HER2- breast cancer
CE/CME ACCREDITED Dr Catherine M Kelly

Watch this two-part activity discussing the latest developments in the management of early breast cancer. Filmed following the ESMO Virtual Congress 2020. Part 1: Watch internationally renowned expert Dr Catherine M Kelly review key data from the ESMO Congress Watch Now Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice Select An Interview

Learning objectives
Learning Objectives
  • Apply new and emerging data for CDK4/6 inhibitors in patients with HR+/HER2- early breast cancer in clinical practice
  • Use the latest results for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer to inform treatment decisions in clinical practice
  • Review emerging real-world data on the outcome of patients with active or a history of cancer who have developed COVID-19 during the COVID-19 pandemic
Breast Cancer, Genitourinary Cancer, Ovarian Cancer
Watch Time: 68 mins
touchCONGRESS
Antibody-drug conjugates for patients with solid tumours: Practical analysis of the latest data from ESMO 2020
CE/CME ACCREDITED Mikel Ross, MSN, RN

Watch this two-part activity discussing the latest developments in antibody-drug conjugates for solid tumours. Filmed following presentations at ESMO 2020. Part 1: Watch internationally renowned expert Mikel Ross review key data from the congress Watch Now Part 2: Choose from leading experts who discuss what the latest data mean for global and regional practice Select An Interview

Learning objectives
Learning Objectives
  • Recognize the antibody drug conjugates (ADCs) that are available for the treatment of solid tumours
  • Summarize how emerging and evolving ADCs may improve outcomes for patients with solid tumours
  • Discuss practical strategies for the management of adverse events associated with approved ADCs for solid tumours
IME
CME activities are developed by touchIME for touchONCOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72